Drug Profile
Research programme: gamma delta T cell therapy - Takeda
Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator GammaDelta Therapeutics
- Developer Takeda
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Solid-tumours in United Kingdom (Parenteral)
- 27 Oct 2021 Cancer immunotherapies is still in early research in the United Kingdom
- 28 Oct 2020 No recent reports of development identified for research development in Cancer in United Kingdom